SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Fraticelli Matthieu) "

Sökning: WFRF:(Fraticelli Matthieu)

  • Resultat 1-2 av 2
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Frid, Emma, 1988-, et al. (författare)
  • A Dual-Task Experimental Methodology for Exploration of Saliency of Auditory Notifications in a Retail Soundscape
  • 2023
  • Ingår i: Proceedings of the 28th International Conference on Auditory Display (ICAD2023): Sonification for the Masses, 2023.
  • Konferensbidrag (refereegranskat)abstract
    • This paper presents an experimental design of a dual-task experiment aimed at exploring the salience of auditory notifications. The first task is a Sustained Attention to Response Task (SART) and the second task involves listening to a complex store soundscape that includes ambient sounds, background music and auditory notifications. In this task, subjects are asked to press a button when an auditory notification is detected. The proposed method is based on a triangulation approach in which quantitative variables are combined with perceptual ratings and free-text question replies to obtain a holistic picture of how the sound environment is perceived. Results from this study can be used to inform the design of systems presenting music and peripheral auditory notifications in a retail environment.
  •  
2.
  • Molina, Berengere, et al. (författare)
  • Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis : a European retrospective study
  • 2023
  • Ingår i: Annals of the Rheumatic Diseases. - : BMJ Publishing Group Ltd. - 0003-4967 .- 1468-2060. ; 82:12, s. 1587-1593
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Eosinophilic granulomatosis with polyangiitis (EGPA) is often associated with glucocorticoid-dependent asthma and/or ear, nose and throat (ENT) manifestations. When immunosuppressants and/or mepolizumab are ineffective, dupilumab could be an option. We describe the safety and efficacy of off-label use of dupilumab in relapsing and/or refractory EGPA.Patients and methods We conducted an observational multicentre study of EGPA patients treated with dupilumab. Complete response was defined by Birmingham Vasculitis Activity Score (BVAS)=0 and prednisone dose ≤4 mg/day, and partial response by BVAS=0 and prednisone dose >4 mg/day. Eosinophilia was defined as an eosinophil count >500/mm3.Results Fifty-one patients were included. The primary indication for dupilumab was disabling ENT symptoms in 92%. After a median follow-up of 13.1 months, 18 patients (35%) reported adverse events (AEs), including two serious AEs. Eosinophilia was reported in 34 patients (67%), with a peak of 2195/mm3 (IQR 1268–4501) occurring at 13 weeks (IQR 4–36) and was associated with relapse in 41%. Twenty-one patients (41%) achieved a complete response and 12 (24%) a partial response. Sixteen (31%) patients experienced an EGPA relapse while on dupilumab, which was associated with blood eosinophilia in 14/16 (88%) patients. The median eosinophil count at the start of dupilumab was significantly lower in relapsers than in non-relapsers, as was the median time between stopping anti-IL-5/IL-5R and switching to dupilumab.Conclusion These results suggest that dupilumab may be effective in treating patients with EGPA-related ENT manifestations. However, EGPA flares occurred in one-third of patients and were preceded by eosinophilia in 88%, suggesting that caution is required.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-2 av 2

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy